Diffuse Large B Cell Lymphoma

The final diagnosis was CD20-negative primary intestinal large B-cell lymphoma with a TP53 mutation arising in the context of poorly controlled CD, a combination that, to the best of our knowledge, has not been previously reported in the literature. This case highlights the diagnostic challenges posed by intestinal lymphomas associated with CD and emphasizes the importance of integrating histopathological, immunophenotypic, and molecular findings to achieve an accurate diagnosis and provide prognostic assessment.

DCA revealed that this fusion model offers a significant clinical net benefit for prognostic risk prediction in DLBCL patients over a wide threshold probability range of 0.05-0.900. The fusion model, combining PET/CT deep features with clinical characteristics, is a dependable prognostic tool for DLBCL, holding substantial promise for clinical application and personalized treatment.

The 5‑index risk model demonstrated robust predictive ability in a real‑world setting, providing a reliable basis for personalized treatment decisions in Chinese DLBCL patients undergoing CAR‑T. Future work will focus on further optimizing the model and conducting multi‑regional validation.

Patient-derived transcriptomes exhibited enrichment of pathways that were functionally related to the gene signatures observed in the xenograft model. These findings suggest that CNS-preferential dissemination in DLBCL is associated with coordinated signaling involving PI3K/ARF6 activation and suppression of S1P-mediated pathways, providing molecular insights with potential implications for risk stratification and therapeutic targeting in sCNSi.

P1, N=14, Recruiting, Abramson Cancer Center at Penn Medicine | Not yet recruiting --> Recruiting

P2, N=66, Not yet recruiting, Ou Bai, MD/PHD

ZR-CHOP demonstrates encouraging activity and acceptable safety in molecularly selected high-risk DLBCL, particularly in the MCD-like subgroup. (ClinicalTrials.gov number, NCT05290337).

P1/2, N=91, Recruiting, Curocell Inc. | Trial completion date: Feb 2028 --> Sep 2030 | Trial primary completion date: May 2023 --> Aug 2030

P=N/A, N=1000, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting

P1/2, N=130, Terminated, Lakefront Biotherapeutics NV | Trial completion date: Jul 2029 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2029 --> May 2026; Following the decision by Galapagos NV to wind down its cell therapy programs, the study was early terminated at the end of the study treatment period for the last subject (27-May-2026).

P2, N=24, Recruiting, University of California, Davis | Trial primary completion date: Feb 2026 --> Oct 2026

P1, N=18, Not yet recruiting, Nathan Denlinger